Sarepta Therapeutics (NASDAQ:SRPT) Given New $193.00 Price Target at Robert W. Baird

Sarepta Therapeutics (NASDAQ:SRPT) had its price target decreased by investment analysts at Robert W. Baird from $200.00 to $193.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price target suggests a potential upside of 60.65% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and issued a $205.00 price target on shares of Sarepta Therapeutics in a report on Thursday. Citigroup dropped their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Finally, William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $182.90.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $7.83 during midday trading on Thursday, reaching $120.14. 1,190,796 shares of the company were exchanged, compared to its average volume of 1,227,808. The stock’s 50-day moving average price is $126.54 and its 200-day moving average price is $132.85. The stock has a market cap of $11.46 billion, a P/E ratio of 266.83 and a beta of 0.81. Sarepta Therapeutics has a one year low of $75.85 and a one year high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.27) earnings per share. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 1.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the transaction, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC boosted its position in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the period. Principal Financial Group Inc. grew its stake in Sarepta Therapeutics by 693.7% in the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after purchasing an additional 317,277 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Sarepta Therapeutics by 2,257.8% during the 1st quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock worth $31,135,000 after acquiring an additional 230,300 shares in the last quarter. Rhumbline Advisers boosted its stake in Sarepta Therapeutics by 146.3% during the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after purchasing an additional 160,942 shares during the period. Finally, Blair William & Co. IL raised its holdings in Sarepta Therapeutics by 303.7% in the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after acquiring an additional 131,112 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.